AKB-6548

· Akebia Therapeutics

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for AKB-6548, covering 2022-05-17 to 2022-07-01. Get the full timeline:

Most recent: Clinical Trial Update: 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia [Phase 2]